Colorectal Cancer study: IDOV-Immune
Official title IDOV-Immune for Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06910657
What this study is testing
What is IDOV-Immune?
This is an investigational medicine being studied as a potential treatment for advanced solid tumors, including colorectal cancer. It is designed to infect and destroy tumor cells while stimulating the immune system.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if the treatment is safe, how well people tolerate it, and what the highest safe dose is. It also looks at how the body handles the drug and if it causes any tumor shrinkage.
- Who it's for
- Adults with advanced solid tumors, such as lung, breast, or colorectal cancer, that have not responded to standard treatments.
- What's involved
- Participants will receive a single IV (intravenous) infusion of the treatment. They will be closely monitored for side effects and changes in their cancer.
- Time commitment
- The study involves a single treatment visit followed by close monitoring for side effects and cancer changes.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy...
- ECOG performance status ≤ 1.
- Measurable disease per RECIST v1.1.
- Adequate organ and bone marrow function.
You likely can't join if
- Prior treatment with an oncolytic virus.
- Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years.
- Active uncontrolled infection requiring systemic treatment.
- History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).
- Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).
- Active or symptomatic autoimmune disease requiring systemic therapy.
See the full eligibility criteria
- Age ≥ 18 years.
- Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.
- ECOG performance status ≤ 1.
- Measurable disease per RECIST v1.1.
- Adequate organ and bone marrow function.
- At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).
- Negative pregnancy test for women of childbearing potential.
- Agreement to use effective contraception during treatment and for 3 months after.
- Ability to provide informed consent and comply with study requirements. Key
- Prior treatment with an oncolytic virus.
- Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years.
- Active uncontrolled infection requiring systemic treatment.
- History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).
- Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).
- Active or symptomatic autoimmune disease requiring systemic therapy.
- Active or untreated CNS metastases (unless stable per protocol).
- Significant cardiac disease (e.g., NYHA Class III/IV heart failure).
- Interstitial lung disease or prior pneumonitis requiring steroids.
- Conditions requiring chronic immunosuppressive therapy.
- Severe skin disorders or history of pancreatitis.
- Bleeding disorders or history of recent serious thromboembolic events.
- Any medical or psychiatric condition that could interfere with study participation.
The study team makes the final eligibility decision.
Where it is enrolling
- St Louis, Missouri, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Westmead, New South Wales, Australia
- Melbourne, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at St Louis, Missouri, United States; Houston, Texas, United States; San Antonio, Texas, United States; Westmead, New South Wales, Australia; Melbourne, Victoria, Australia. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.